{
  "docId": "019de075-0f3e-7563-9ac8-6248b1eac169",
  "docSlug": "df5bd8b83b2912100a1eb82b66046bd0",
  "documentTitle": "Theravance Biopharma | Results Presentation Deck | 41 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 41,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "cover",
  "function": "front_matter",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-0f3e-7563-9ac8-6248b1eac169/8",
  "deckHref": "/decks/019de075-0f3e-7563-9ac8-6248b1eac169",
  "deckJsonHref": "/decks/019de075-0f3e-7563-9ac8-6248b1eac169.json",
  "deckAnchorHref": "/decks/019de075-0f3e-7563-9ac8-6248b1eac169#slide-8",
  "components": [
    {
      "bbox": {
        "x": 0.01,
        "y": 0.91
      },
      "kind": "image",
      "text": "Theravance Biopharma logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "219cfee0-1d0d-406c-bc81-3c130b34ac38",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "x": 0.06,
        "y": 0.16
      },
      "kind": "image",
      "text": "YUPELRI logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b1cce588-6b2f-42af-aa33-36bed14dbbca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "x": 0.07,
        "y": 530
      },
      "kind": "list",
      "text": "FDA-approved for maintenance treatment of COPD. First and only once-daily, LAMA (long-acting muscarinic agent) nebulized maintenance medicine for COPD. Co-promotion agreement with VIATRISTM (35% / 65% Profit Share)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35f86512-6819-493a-8f0e-6735b52f2103",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Slide recipe: Cover",
      "slug": "cover-slide",
      "agent": "designer",
      "layer": "slide",
      "matchId": "9eda3d76-949f-4a60-93e9-445364b135c1",
      "evidence": "YUPELRI revefenacin inhalation solution",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 40,
      "from": 5,
      "beatId": "18f97180-6c3c-4b05-a378-979222504b06",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Before-After",
      "beatSlug": null,
      "evidence": "Multiple slides show progress and growth using before-after comparisons.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}